Form 4 for XERS Xeris Biopharma Holdings, Inc.
Accepted 2024-06-05 00:00:00 ET · period of report 2024-06-05 · accession 0001867096-24-000106 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-06-05 | 2024-06-05 | XERS | JOHNSON JOHN | Dir | A - Grant | $0.00 | +50.0K | 891.0K | +6% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-06-05 | A | A | 50,000 | $0.00 | 890,983 | D | — | — | (F1) These shares were acquired pursuant to a restricted stock unit award under the Company's 2018 Stock Option and Incentive Plan. Each restricted stock represents a contingent right to receive one share of the Company's common stock. These shares shall vest in full upon the earlier to occur of June 5, 2025 or the date of the Company's next annual meeting of stockholders. |